Collagen Protein Versus Placebo on Muscle Recovery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-30
SponsorUniversity of Central Florida

About this trial

This study is focused on exploring the gap in the literature by comparing the effects of collagen protein versus placebo supplementation on the musculotendinous unit following muscle damaging protocol. Thus, the purpose of this study is to identify and compare the effect of collagen protein versus placebo supplementation on indirect markers of musculotendinous unit recovery following eccentric calf exercises.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Males between the ages of 18-30 years old

Determined to be healthy by PAR-Q+ and the HHQ

Disqualifiers

Untrained (no resistance training in the past 3 months)

Any response of "yes" on the PAR-Q+; exclusion criteria noted on the HHQ

Allergy to bovine collagen or maltodextrin

Trial design

Design model

Single group

Treatments tested in this trial

  • Collagen

    Dietary supplement

    Participants will consume two 30-g amount of collagen peptides derived from bovine hide (commercially available as Vital Proteins or Peptan) mixed in 300 ml of orange gatorade zero.

  • Maltodextrin

    Dietary supplement

    Participants will consume two 30-g amount of pure maltodextrin mixed in 300 ml of orange gatorade zero.

Treatment groups

36 Participants
are divided into 3 treatment groups
Group A: CollagenExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention
Group C: ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Calf muscle thickness

Portable B-mode Ultrasound (GE Logiq e BT12, GE Healthcare, Milwaukee, WI, USA) and a multi-frequency linear- array probe (12 L-RS, 5-13 MHz, 38.4-mm field of view, GE Healthcare, Milwaukee, WI, USA) will be used to determine changes in muscle thickness of the randomized leg. The distance between the medial point of the knee joint space and the central point of the medial malleolus will be measured at 70% and ultrasound gel will be placed on this location prior to measurement. The highest and mean values of 3-5 measurements will be recorded for each assessment. All measurements will be done on one randomized leg.

Time frame
5 days

Secondary outcomes

1

Achilles tendon thickness.

Achilles tendon will be scanned using a B-mode US imaging device (GE Logiq e, GE Healthcare,Wauwatosa, WI, USA) and a multi-frequency linear-array probe (12 L-RS, 5-13 MHz, 38.4-mm field of view; GE Healthcare). The same researcher will perform the assessments. All ultrasound imaging analyses will be performed using Image-J software 1.8.0 (National Institute of Health, Bethesda, MD, USA). Achilles tendon length will be determined using the segmented line function between calcaneal notch and muscle-tendon junction along the midline of the Achilles tendon. Additionally, sagittal images of the Achilles tendon will be collected with the ankle passively dorsiflexed to approximately 90 degrees. Tendon thickness will be measured at reference point of 2 cm proximal to the superior aspect of the calcaneus.

Time frame
5 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: